ALX40-4C: To start Canadian Phase I trials in October

Allelix Biopharmaceuticals Inc. (Tor:AXB) Product: ALX40-4C, which prevents the HIV viral protein Tat from binding to the TAR gene, thereby preventing HIV replication Indication: Treat AIDS Status: To...